|
(A) Day 8
|
|---|
| |
Treatment
|
|---|
| |
PBS (n = 4)
|
W3/25 (n = 2)
|
OX35 (n = 4)
|
RIB5/2 (n = 3)
|
|---|
|
Antigen (FACS)
|
%
|
MFI
|
%
|
MFI
|
%
|
MFI
|
%
|
MFI
|
|---|
|
Isotype control
|
0 ± 0.0
|
107 ± 9.0
|
4 ± 0.5
|
98 ± 2.0
|
1 ± 0.3
|
82 ± 3.3
|
0 ± 0.0
|
86 ± 7.7
|
|
CD3
|
70 ± 5.5
|
122 ± 1.7
|
47 ± 5.0
|
99 ± 1.5
|
31 ± 1.9*
|
93 ± 1.5*
|
28 ± 7.2*
|
95 ± 0.7*
|
|
CD8
|
21 ± 1.0
|
162 ± 1.3
|
27 ± 3.0
|
110 ± 1.5
|
33 ± 2.0*
|
109 ± 5.0*
|
39 ± 3.2*
|
111 ± 0.3*
|
|
CD4 (W3/25)
|
55 ± 3.2
|
116 ± 0.8
|
7 ± 2.5
|
98 ± 1.5
|
23 ± 1.7*
|
97 ± 1.2*
|
8 ± 1.5*
|
95 ± 0.7*
|
|
CD4 (OX35)
|
52 ± 7.5
|
150 ± 0.9
|
45 ± 8.0
|
93 ± 3.0
|
26 ± 4.1
|
122 ± 2.4
|
8 ± 1.2*
|
121 ± 1.0*
|
|
Mouse IgG
|
1 ± 0.3
|
105 ± 1.9
|
18 ± 2.0
|
101 ± 0.5
|
2 ± 0.3
|
79 ± 2.4*
|
1 ± 0.0
|
85 ± 3.2*
|
|
(B) Day 13
|
| |
Treatment
|
| |
PBS (n = 3)
|
W3/25 (n = 4)
|
OX35 (n = 4)
|
RIB5/2 (n = 3)
|
|
Antigen (FACS)
|
%
|
MFI
|
%
|
MFI
|
%
|
MFI
|
%
|
MFI
|
|
Isotype control
|
1 ± 0.6
|
78 ± 1.3
|
2 ± 1.7
|
87 ± 4.1
|
1 ± 0.3
|
81 ± 3.7
|
1 ± 0.3
|
71 ± 1.7
|
|
CD3
|
53 ± 2.3
|
142 ± 0.6
|
44 ± 2.3
|
116 ± 3.0*
|
39 ± 2.5*
|
94 ± 1.0*
|
38 ± 1.5*
|
96 ± 2.0*
|
|
CD8
|
20 ± 3.8
|
144 ± 1.5
|
23 ± 1.7
|
128 ± 3.2*
|
30 ± 7.4
|
108 ± 1.6*
|
41 ± 2.3*
|
113 ± 0.9*
|
|
CD4 (W3/25)
|
46 ± 1.0
|
110 ± 1.9
|
28 ± 2.0*
|
109 ± 1.9
|
25 ± 2.9*
|
104 ± 1.6
|
20 ± 0.9*
|
106 ± 0.7
|
|
CD4 (OX35)
|
46 ± 0.7
|
154 ± 0.7
|
29 ± 3.8*
|
144 ± 5.9
|
23 ± 5.3*
|
102 ± 2.6*
|
17 ± 2.5*
|
116 ± 6.4*
|
|
Mouse IgG
|
4 ± 2.5
|
77 ± 2.5
|
9 ± 2.0
|
91 ± 3.5*
|
1 ± 0.2
|
82 ± 2.7
|
2 ± 0.0
|
76 ± 1.2
|
- Results of surface staining are expressed as the mean ± SEM of the percentage of positive cells and the mean fluorescence intensity (MFI). FACS = flow cytometry. *P ≤ 0.05 in comparison with PBS control.
